ConductScience.org, home

Disease · MONDO_0005338

Comparisons in its trials99

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Brinz/Brim vs Brinz+Brim: serious adverse events11 of 4528 of 436888NCT01309204Trial comparisons
Travoprost 0.003% vs TRAVATAN: serious adverse events5 of 4427 of 421863NCT01453855Trial comparisons
Travoprost vs Latanoprost: serious adverse events5 of 3637 of 363726NCT00690794Trial comparisons
Travoprost vs Latanoprost: serious adverse events4 of 3536 of 348701NCT00761319Trial comparisons
PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: deaths from any cause0 of 3370 of 341678NCT03450629Trial comparisons
PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: serious adverse events1 of 3373 of 341678NCT03450629Trial comparisons
Tafluprost vs Timolol Maleate: serious adverse events2 of 3207 of 323643NCT01026831Trial comparisons
Brinzolamide 1% Ophthalmic Suspension vs Azopt 1% Ophthalmic Suspension: deaths from any cause0 of 3200 of 318638NCT03896633Trial comparisons
Brinzolamide 1% Ophthalmic Suspension vs Azopt 1% Ophthalmic Suspension: serious adverse events0 of 3202 of 318638NCT03896633Trial comparisons
BRIN-20-01 vs Azopt®: deaths from any cause0 of 2970 of 300597NCT05022004Trial comparisons
BRIN-20-01 vs Azopt®: serious adverse events0 of 2971 of 300597NCT05022004Trial comparisons
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): deaths from any cause1 of 3480 of 217565NCT02914509Trial comparisons
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): Number of Participants With Serious Adverse Events7 of 3486 of 217565NCT02914509Trial comparisons
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): serious adverse events7 of 3486 of 217565NCT02914509Trial comparisons
Perrigo Active vs Reference Active: deaths from any cause0 of 2490 of 246495NCT04024072Trial comparisons
Perrigo Active vs Reference Active: serious adverse events0 of 2491 of 246495NCT04024072Trial comparisons
Perrigo Active vs Reference Active: deaths from any cause1 of 2210 of 226447NCT04944290Trial comparisons
Perrigo Active vs Reference Active: serious adverse events2 of 2214 of 226447NCT04944290Trial comparisons
BOL-303259-X vs Timolol: Response Rate - IOP Reduction ≥ 25%99 of 28426 of 133417NCT01749904Trial comparisons
BOL-303259-X vs Timolol: Response Rate - IOP ≤ 18 mm Hg65 of 28415 of 133417NCT01749904Trial comparisons

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005338/comparisons